Objective
- Systemic lupus erythematosus (SLE) trials suffer from equivocal or failed trial outcomes.
- The objective of this work is to use a quantitative systems pharmacology (QSP) model to establish an analysis framework that characterizes trial outcome trade-offs stemming from disease heterogeneity and entry criteria.
- This framework aims to improve prediction of treatment response to inform trial design and precision medicine.